Bid guide
How to bid on Pharmacology and Toxicology for Therapeutics Program (PTTP) IDIQ Contracts for NINDS
What the agency is buying and why it matters
The National Institute on Neurological Disorders and Stroke (NINDS) is seeking to extend four existing Indefinite Quantity Indefinite Delivery (IDIQ) contracts for its Pharmacology and Toxicology for Therapeutics Program (PTTP). This program supports preclinical pharmacology, pharmacokinetic, toxicology, safety, and IND-enabling studies for potential therapeutics. These services are vital for drug development within the NIH Blueprint Neurotherapeutics Network (BPN) and other NINDS projects, helping to advance compounds through early development and regulatory filings like FDA Investigational New Drug (IND) applications.
The extension will allow current contractors to continue providing critical services, including in vivo pharmacokinetic studies, preclinical acute toxicity evaluations, subacute and subchronic toxicity evaluations, safety pharmacology studies, genotoxicity assessments, and in vitro predictive ADMET assays. This ensures ongoing support for assessing promising candidates' pharmacokinetics, toxicology, and safety.
Key dates and what happens at the deadline
This is a Request for Information (RFI) and a notice of intent to extend existing contracts, not a competitive solicitation for new awards. The deadline for submitting capability statements or objections is August 18, 2026, at 3:00 PM Eastern Time. While the government will consider responses, the decision to proceed with the proposed contract modification is at its sole discretion.
The proposed contract modification will extend the ordering period for the four existing IDIQ contracts by two years, from September 12, 2026, to September 12, 2028. This extension bridges the gap until the PTTP requirement can be recompeted and new IDIQ contracts are awarded.
Who this opportunity suits
This opportunity is primarily for businesses with expertise in preclinical pharmacology, toxicology, and drug development services. The work involves specialized studies such as analytical method development, in vivo pharmacokinetic studies, various toxicity evaluations (acute, subacute, subchronic, long-term), safety pharmacology, genotoxicity, and in vitro ADMET assays. The relevant North American Industry Classification System (NAICS) code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), with a size standard of 1,000 employees.
While this is not a new competitive solicitation, it is relevant for firms that believe they could provide these services and wish to express interest or object to the proposed contract extension. It is also an indicator of future competitive opportunities in this specialized field.
How to respond
To access the original source of this opportunity, click “View original source” on the portal. If the first click takes you to the portal’s homepage, click the link again to go directly to the bid. You may need a free account to view documents, though this is not always required.
Interested parties should submit capability statements or objections to the proposed contract modification. Any potential offeror must have an active registration in the System for Award Management (SAM) and provide their Unique Entity Identifier (UEI) and Taxpayer Identification Number (TIN).
Practical tips for preparing a competitive response
Even for an RFI or notice of intent, a strong capability statement is crucial. Clearly articulate your firm's experience and expertise in preclinical pharmacology, toxicology, and IND-enabling studies. Highlight specific projects or services that align with the scope described, such as pharmacokinetic studies, various toxicity assessments, and safety pharmacology.
Ensure your SAM registration is active and up-to-date, including your UEI and TIN. This is a mandatory requirement for any engagement with the government. If you are submitting an objection, clearly and concisely state your reasons, providing evidence or arguments that support your position regarding the proposed contract extension. Focus on how your firm could better meet the agency's needs or why the extension is not in the government's best interest.
See the live bid — deadline, agency details, and how to respond
Dates and requirements can change via addenda; always verify on the bid page and at the original source before responding.
View this bid on BiddingSimpleThis guide was prepared by BiddingSimple from the solicitation’s public posting. It is not official guidance from National Institute on Neurological Disorders and Stroke; the original posting controls.